- Home
- ACIU vs LCNB Comparison
ACIU vs LCNB Comparison
Compare ACIU & LCNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- LCNB
- Stock Information
- Founded
- ACIU 2003
- LCNB 1877
- Country
- ACIU Switzerland
- LCNB United States
- Employees
- ACIU N/A
- LCNB N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- LCNB Major Banks
- Sector
- ACIU Health Care
- LCNB Finance
- Exchange
- ACIU Nasdaq
- LCNB Nasdaq
- Market Cap
- ACIU 213.3M
- LCNB 201.3M
- IPO Year
- ACIU 2016
- LCNB N/A
- Fundamental
- Price
- ACIU $2.14
- LCNB $14.49
- Analyst Decision
- ACIU Strong Buy
- LCNB
- Analyst Count
- ACIU 1
- LCNB 0
- Target Price
- ACIU $12.00
- LCNB N/A
- AVG Volume (30 Days)
- ACIU 162.6K
- LCNB 20.9K
- Earning Date
- ACIU 08-05-2025
- LCNB 07-22-2025
- Dividend Yield
- ACIU N/A
- LCNB 6.09%
- EPS Growth
- ACIU N/A
- LCNB 186.58
- EPS
- ACIU N/A
- LCNB 1.49
- Revenue
- ACIU $36,362,036.00
- LCNB $86,864,000.00
- Revenue This Year
- ACIU N/A
- LCNB N/A
- Revenue Next Year
- ACIU $533.21
- LCNB $6.72
- P/E Ratio
- ACIU N/A
- LCNB $9.69
- Revenue Growth
- ACIU 86.71
- LCNB 22.73
- 52 Week Low
- ACIU $1.43
- LCNB $13.34
- 52 Week High
- ACIU $3.98
- LCNB $17.92
- Technical
- Relative Strength Index (RSI)
- ACIU 49.10
- LCNB 42.94
- Support Level
- ACIU $2.05
- LCNB $14.21
- Resistance Level
- ACIU $2.50
- LCNB $14.80
- Average True Range (ATR)
- ACIU 0.20
- LCNB 0.35
- MACD
- ACIU -0.03
- LCNB -0.13
- Stochastic Oscillator
- ACIU 20.00
- LCNB 21.97
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.